Hair loss treatments, ranked by the evidence

Hair loss is one of the most heavily marketed corners of health, and the gap between what sells and what the trials support is wide. This hub page maps the landscape by strength of evidence. Each treatment gets a short verdict here, with deeper spoke pieces to follow. Throughout, the standard is simple: randomized controlled trials, systematic reviews, FDA labels, and dermatology guidance. Where the evidence is thin, this page says so.

The common cause: androgenetic alopecia

The large majority of persistent hair loss in adults is androgenetic alopecia (AGA), also called male pattern and female pattern hair loss. It is strongly heritable, and twin studies attribute the large majority of the predisposition to genetics. Roughly half of white men are affected by age 50, and about 80 percent by age 70 (StatPearls, NCBI). It is common in women too, rising notably after menopause.

The mechanism is hormonal. The enzyme 5-alpha-reductase converts testosterone into dihydrotestosterone (DHT). In genetically susceptible follicles, DHT binds androgen receptors and shortens the growth (anagen) phase of the hair cycle. Over successive cycles the follicles miniaturize, turning thick terminal hairs into fine, short vellus hairs, which produces the visible thinning pattern (JAAD International, 2023). This matters for treatment: the drugs with the best evidence either extend the growth phase (minoxidil) or block DHT production (finasteride, dutasteride).

Strongest evidence: topical minoxidil and oral finasteride

Topical minoxidil. Verdict: strong evidence, first-line for both sexes. A systematic review and meta-analysis found topical minoxidil produced more hair than placebo, with a mean difference of about 16.7 total hairs and 20.9 non-vellus hairs per measured area (Gupta & Charrette, 2015). It is FDA-approved for men and women. It does not block DHT; it prolongs the growth phase, so the benefit lasts only while use continues.

Oral finasteride (men). Verdict: strong long-term evidence in men. Finasteride 1 mg blocks type II 5-alpha-reductase, lowering scalp DHT. In the pivotal trials, finasteride raised scalp hair counts above baseline (about +91 hairs at one year and +56 at two years in the measured area), and at five years finasteride users remained a net +38 above baseline while the placebo group had lost a mean of 239 hairs in the same area (PROPECIA FDA label; long-term 5-year study, 2002). The trade-off is a modest excess of sexual side effects in year one, 4.2 percent versus 2.2 percent on placebo, including decreased libido and erectile dysfunction, with reported rates declining over time (PROPECIA FDA label). Persistent symptoms after stopping are reported but come mostly from self-selected samples, not representative trials, so the true rate is uncertain.

Combining topical minoxidil with finasteride outperforms either alone in pooled trial data (systematic review and meta-analysis, 2020).

The newer and adjacent options

Low-dose oral minoxidil. Verdict: promising, limited head-to-head data. A double-blind randomized trial in 90 men found daily oral minoxidil (5 mg) performed similarly to topical minoxidil (5 percent) over 24 weeks, without proving superior (JAMA Dermatology, 2024). It is an off-label option that some people find easier to use than the topical.

Dutasteride. Verdict: likely more potent than finasteride, less long-term safety data. Dutasteride blocks both type I and type II 5-alpha-reductase. In a randomized active-controlled trial, dutasteride 0.5 mg increased hair count more than finasteride 1 mg at 24 weeks (Olsen et al., JAAD). It is FDA-approved for enlarged prostate, not hair loss in the United States.

Topical finasteride. Verdict: trial-supported, not FDA-approved in the US. A phase III randomized trial found a 0.25 percent finasteride spray improved hair growth comparably to oral finasteride, with plasma drug levels more than 100 times lower (Piraccini et al., JEADV, 2022). It remains unapproved by the FDA.

Microneedling and platelet-rich plasma (PRP). Verdict: adjuncts with small, heterogeneous trials. Both show signals in small studies, often as add-ons to minoxidil, but systematic reviews note few trials, varied protocols, and modest quality (systematic review, 2025). They are not replacements for the first-line drugs.

Low-level laser therapy (LLLT). Verdict: FDA-cleared devices, mixed evidence. Some devices are FDA-cleared and network meta-analyses place LLLT alongside other active treatments at 24 weeks (network meta-analysis, 2023), but trials are short and industry-linked, so confidence is moderate.

The low-evidence hype

Most supplements. Verdict: little or no controlled evidence for reversing pattern hair loss.

Biotin. Verdict: helps only genuine deficiency. A systematic review found biotin improved hair only in people with an underlying deficiency or specific disorder, which is uncommon on a normal diet (JCAD review; MDPI systematic review, 2025). High-dose biotin can also distort some lab tests.

Rosemary oil. Verdict: one small trial, widely overstated online. The viral claim traces to a single six-month trial of about 100 people that found rosemary oil roughly comparable to 2 percent minoxidil (Panahi et al., SKINmed, 2015). One small study is a starting point, not proof.

Reading before-and-after marketing skeptically

Marketing images exploit variables that have nothing to do with a product: lighting, wet versus dry hair, camera angle, hair length, and styling. Trials control for these using standardized photography and hair counts in a fixed scalp area, which is why hair-count figures, not glossy photos, carry the weight here. Be wary of testimonials, undisclosed sponsorship, and “clinically proven” claims with no citation.

Realistic expectations

The bottom line the evidence supports: proven treatments slow loss and partly reverse it, they work best early, and they require continued use. Because minoxidil and the DHT blockers act only while present, stopping generally reverses the gains within months as the underlying process resumes. Results build over 6 to 12 months, and maintenance is indefinite.

This article is evidence reporting, not medical advice. Treatment decisions, including drugs, dosing, and side-effect risks, should be made with a qualified clinician who knows your history.

Common questions

What is the single most effective hair loss treatment?

For men, the combination of oral finasteride plus topical minoxidil outperforms either alone in pooled trial data. For women, topical minoxidil is the first-line option with the strongest evidence. There is no cure; these treatments slow loss and partly reverse it while used.

Does finasteride work for women?

The evidence is weak. A randomized placebo-controlled trial found finasteride 1 mg ineffective in postmenopausal women with female pattern hair loss, and it is not FDA-approved for women. Topical minoxidil is the better-supported choice for women.

Do I have to keep using these treatments forever?

Effectively yes, to keep the results. Minoxidil, finasteride, and dutasteride act only while present in the body. Trials and clinical experience show that stopping generally reverses the gains within a few months as the underlying miniaturization process resumes.

Does biotin regrow hair?

Only if you have a genuine biotin deficiency, which is uncommon on a normal diet. Systematic reviews found no reliable benefit in people who are not deficient. High-dose biotin can also interfere with some blood tests.

Is rosemary oil as good as minoxidil?

That claim rests on a single small six-month trial of about 100 people that found rough comparability to 2 percent minoxidil. One small study is not enough to treat rosemary oil as an equal to a treatment backed by many controlled trials.